Coherus Oncology, Inc. (CHRS) Current Ratio
- Current ratio · latest quarter: Value 1.77×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 1.77× | Current assets / current liabilities. $133.79M ÷ $75.51M ≈ 1.77× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 133.79M USD | Assets, Current |
| Current obligations | 75.51M USD | Liabilities, Current |
| Cash and equivalents | 82.92M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | 22.38M USD | Marketable Securities, Current |
| Customer receivables | (m) | Accounts Receivable, after Allowance for Credit Loss, Current |
| Inventory | 5.67M USD | Inventory, Net |
| Payables | 13.17M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $133.79M | $75.51M | $82.92M | $22.38M | (m) | $5.67M | $13.17M | (m) | 1.77× |
| 2026-03-31 | $206.03M | $132.33M | $115.24M | $51.81M | (m) | $4.83M | $11.48M | (m) | 1.56× |
| 2025-12-31 | $206.71M | $140.39M | $88.88M | $83.25M | (m) | $3.17M | $9.91M | (m) | 1.47× |
| 2025-09-30 | $460.95M | $372.30M | $103.35M | $88.31M | (m) | $2.05M | $24.89M | (m) | 1.24× |
| 2025-06-30 | $380.20M | $263.63M | $216.89M | $20.74M | (m) | $4.51M | $37.62M | (m) | 1.44× |
| 2025-03-31 | $310.18M | $255.04M | $82.41M | (m) | (m) | $3.52M | $40.93M | (m) | 1.22× |
| 2024-12-31 | $341.58M | $282.98M | $125.99M | (m) | (m) | $4.21M | $28.46M | (m) | 1.21× |
| 2024-09-30 | $369.02M | $295.57M | $97.69M | (m) | (m) | $47.64M | $21.89M | (m) | 1.25× |
| 2024-06-30 | $557.93M | $463.00M | $159.24M | (m) | (m) | $62.16M | $76.82M | (m) | 1.21× |
| 2024-03-31 | $627.48M | $538.30M | $259.77M | (m) | (m) | $61.98M | $38.29M | (m) | 1.17× |
| 2023-12-31 | $475.63M | $331.77M | $102.89M | $14.86M | (m) | $2.09M | $35.22M | (m) | 1.43× |
| 2023-09-30 | $444.37M | $239.66M | $80.26M | $50.82M | (m) | $66.78M | $37.09M | (m) | 1.85× |
| 2023-06-30 | $385.48M | $169.44M | $72.92M | $71.79M | (m) | $63.99M | $29.28M | (m) | 2.28× |
| 2023-03-31 | $315.93M | $123.41M | $16.14M | $111.94M | (m) | $49.41M | $23.23M | (m) | 2.56× |
| 2022-12-31 | $381.23M | $138.69M | $63.55M | $128.13M | (m) | $38.79M | $11.53M | (m) | 2.75× |
| 2022-09-30 | $448.27M | $171.32M | $286.81M | (m) | (m) | $27.72M | $9.92M | (m) | 2.62× |
| 2022-06-30 | $446.78M | $140.75M | $275.48M | (m) | (m) | $31.74M | $17.49M | (m) | 3.17× |
| 2022-03-31 | $512.44M | $153.75M | $325.68M | (m) | (m) | $36.95M | $21.09M | (m) | 3.33× |
| 2021-12-31 | $602.32M | $165.33M | $417.19M | (m) | (m) | $37.64M | $16.16M | (m) | 3.64× |
| 2021-09-30 | $673.04M | $320.35M | $360.54M | $108.17M | (m) | $37.58M | $45.71M | (m) | 2.10× |
| 2021-06-30 | $660.01M | $287.05M | $329.74M | $124.68M | (m) | $39.67M | $14.57M | (m) | 2.30× |
| 2021-03-31 | $617.26M | $257.60M | $259.49M | $140.01M | (m) | $51.61M | $15.48M | (m) | 2.40× |
| 2020-12-31 | $767.48M | $145.65M | $541.16M | (m) | (m) | $44.23M | $15.20M | (m) | 5.27× |
| 2020-09-30 | $726.92M | $133.43M | $292.46M | $210.97M | (m) | $35.25M | $11.99M | (m) | 5.45× |
| 2020-06-30 | $675.86M | $129.76M | $224.62M | $231.88M | (m) | $27.19M | $21.18M | (m) | 5.21× |
| 2020-03-31 | $395.18M | $119.01M | $193.25M | (m) | (m) | $16.44M | $20.48M | (m) | 3.32× |
| 2019-12-31 | $343.01M | $114.97M | $177.67M | (m) | (m) | $9.81M | $25.98M | (m) | 2.98× |
| 2019-09-30 | $276.38M | $82.70M | $165.12M | $5.38M | (m) | $7.67M | $13.71M | (m) | 3.34× |
| 2019-06-30 | $205.63M | $61.23M | $105.93M | $5.99M | (m) | $4.33M | $19.22M | (m) | 3.36× |
| 2019-03-31 | $159.16M | $41.41M | $81.52M | $14.92M | (m) | $2.31M | $11.17M | (m) | 3.84× |
| 2018-12-31 | $84.43M | $33.26M | $72.36M | (m) | (m) | $1.66M | $15.29M | (m) | 2.54× |
| 2018-09-30 | $130.31M | $24.54M | $101.20M | $15.97M | (m) | (m) | $7.64M | (m) | 5.31× |
| 2018-06-30 | $172.78M | $22.20M | $130.00M | $29.81M | (m) | (m) | $13.30M | (m) | 7.78× |
| 2018-03-31 | $112.24M | $27.62M | $82.02M | $13.14M | (m) | (m) | $14.33M | (m) | 4.06× |
| 2017-12-31 | $145.48M | $28.39M | $126.91M | (m) | (m) | (m) | $15.48M | (m) | 5.12× |
| 2017-09-30 | $171.60M | $31.43M | $135.56M | $14.49M | (m) | (m) | $10.14M | (m) | 5.46× |
| 2017-06-30 | $153.34M | $35.95M | $73.35M | $44.98M | (m) | (m) | $15.75M | (m) | 4.27× |
| 2017-03-31 | $208.26M | $47.30M | $124.92M | $49.90M | $26.00K | (m) | $12.56M | (m) | 4.40× |
| 2016-12-31 | $161.49M | $56.38M | $124.95M | (m) | $1.86M | (m) | $19.71M | (m) | 2.86× |
| 2016-09-30 | $177.32M | $58.39M | $159.68M | (m) | $419.00K | (m) | $22.88M | (m) | 3.04× |
| 2016-06-30 | $236.83M | $108.28M | $220.92M | (m) | $419.00K | (m) | $17.43M | (m) | 2.19× |
| 2016-03-31 | $211.58M | $92.92M | $179.56M | (m) | $1.20M | (m) | $17.90M | (m) | 2.28× |
| 2015-12-31 | $197.39M | $106.02M | $158.23M | (m) | $1.56M | (m) | $25.95M | (m) | 1.86× |
| 2015-09-30 | $189.30M | $82.52M | $153.69M | (m) | $540.00K | (m) | $25.19M | (m) | 2.29× |
| 2015-06-30 | $239.59M | $69.95M | $206.09M | (m) | $1.45M | (m) | $14.09M | (m) | 3.43× |
| 2015-03-31 | $143.90M | $51.91M | $115.14M | (m) | $2.02M | (m) | $10.87M | (m) | 2.77× |
| 2014-12-31 | $179.14M | $51.78M | $150.39M | (m) | $2.42M | (m) | $8.78M | (m) | 3.46× |
| 2014-09-30 | $118.88M | $48.08M | $100.88M | (m) | (m) | (m) | $4.41M | (m) | 2.47× |
| 2013-12-31 | $45.68M | $53.70M | $39.55M | (m) | $278.00K | (m) | $3.30M | (m) | 0.85× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |